交银国际研究 公司更新 业绩稳健，派息回馈持续，维持买入 买入 1 年股价表现 8/24 12/24 4/25 8/25 -20% -10% 0% 10% 20% 30% 40% 50% 3808 HK 恒生指数 股份资料 | 重卡 | 收盘价 | | 目标价 | | 潜在涨幅 | 2025 年 8 月 28 日 | | --- | --- | --- | --- | --- | --- | --- | | 港元 | | 23.32 | 港元 | 26.45 | +13.4% | | | 中国重汽 (3808 HK) | | | | | | | 李柳晓, PhD, CFA joyce.li@bocomgroup.com (852) 3766 1854 财务数据一览 | 年结12月31日 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 收入 (百万人民币) | 85,498 | 95,062 | 109,886 | 114,683 | 120,158 | | 同比增长 (%) | 43.9 | 11. ...

Investment Rating - The report maintains a "Buy" rating for the company, Shenzhou International (2313 HK), with a target price adjusted to HKD 84.00, indicating a potential upside of 41.5% from the current price of HKD 59.35 [1][7][12]. Core Insights - The company has shown steady revenue growth in the first half of 2025, with a year-on-year increase of 15.3% to RMB 14.97 billion, primarily driven by volume growth, while the average selling price saw a slight increase of 0.8% [6][7]. - Net profit for the same period rose by 8.4% to RMB 3.18 billion, although the gross margin decreased to 27.1%, down 1.9 percentage points year-on-year, influenced by ongoing employee salary increases [6][7]. - The report highlights a significant growth in leisure products, which surged by 37.4%, while sports products grew by 9.9% in the European and American markets [6][7]. - The company is expanding its overseas production capacity, with a new fabric factory in Vietnam set to begin operations by the end of 2025 and a new garment factory in Cambodia already operational [6][7]. Financial Summary - Revenue projections for the company have been slightly reduced for 2025 and 2026 by 3-4%, with net profit forecasts adjusted down by 16% due to more conservative gross margin assumptions [6][7]. - The expected revenue for 2025 is RMB 32.17 billion, with a projected net profit of RMB 6.55 billion, reflecting a year-on-year growth of 4.9% [5][13]. - The report anticipates a gross margin of 27.2% for 2025, which is a decrease from previous estimates, and a net profit margin of 20.4% [8][14].

上 市 公 司 社会服务 2025 年 08 月 28 日 中国东方教育 (00667) ——紧抓高中培训市场景气提升，业绩持续向好可期 报告原因：强调原有的投资评级 买入（维持） | 市场数据： | 2025 年 08 月 27 日 | | --- | --- | | 收盘价（港币） | 8.08 | | 恒生中国企业指数 | 9020.26 | | 52 周最高/最低（港币） | 9.15/2.20 | | H 股市值（亿港币） | 178.54 | | 流通 H 股（百万股） | 2,209.69 | | 汇率（人民币/港币） | 1.0953 | 一年内股价与基准指数对比走势： -5% 195% 395% HSCEI 中国东方教育 资料来源：Bloomberg 相关研究 证券分析师 黄哲 A0230513030001 huangzhe@swsresearch.com 联系人 黄哲 (8621)23297818× huangzhe@swsresearch.com 投资要点： 中国东方教育发布 2025 半年报，公司 1H25 收入 21.86 亿元，同比增长 10.2%。经调整归母净利润 4.16 亿元 ...

证 券 研 究 报 告 华润万象生活（01209.HK）2025 年中报点评 推荐（维持） 购物中心保持高增，核心净利 100%分红 事项： 2025 年上半年实现营收 85.24 亿元，同比增长 6.5%；归母净利润 20.3 亿元， 同比增长 7.4%；核心归母净利润 20.11 亿元，同比增长 15%。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 17,043 | 18,332 | 20,518 | 23,064 | | 同比增速(%) | 15% | 8% | 12% | 12% | | 归母净利润(百万) | 3,629 | 4,257 | 4,894 | 5,622 | | 同比增速(%) | 24% | 17% | 15% | 15% | | 每股盈利(元) | 1.59 | 1.87 | 2.14 | 2.46 | | 市盈率(倍) | 22 | 19 | 16 | 14 | | 市净率(倍) | 5 | 4 ...

Investment Rating - The report maintains a "Strong Buy" rating for Meituan-W (03690.HK) [1][3] Core Views - The Q2 performance of Meituan was impacted by increased competition, with revenue of 91.84 billion (+11.7%) and adjusted net profit of 1.49 billion (-89.0%) [1][6] - Despite the competitive pressures, the long-term outlook for the company's core domestic business remains positive due to its competitive advantages and growth potential, while overseas operations present new growth opportunities [1][6] Financial Data and Valuation - Revenue projections for the upcoming years are as follows: - 2023: 276.85 billion - 2024: 337.59 billion - 2025E: 370.60 billion - 2026E: 428.95 billion - 2027E: 493.90 billion - Adjusted net profit estimates show significant fluctuations, with a projected loss of 15.60 billion in 2025E, followed by a recovery in subsequent years [2][8] - The target price is set at 141.90 HKD, with the current stock price at 116.3 HKD, indicating potential upside [3][6] Business Segment Performance - Core local commerce revenue growth slowed to 7.7% in Q2, while new business revenue increased by 22.8% [6] - The food delivery segment experienced stable growth in order volume, but profitability was affected by increased competition and subsidies [6] - The in-store segment showed a GTV growth of over 20%, but revenue growth is expected to decline due to competitive pressures [6] Future Outlook - The report anticipates that Q3 will see continued competitive intensity, leading to increased losses in the food delivery segment [6] - Long-term growth potential remains strong, with expectations for core local business GMV to reach approximately 2.7 trillion in 2025E [6][7]

医药生物 2025 年 08 月 28 日 药明合联 (02268) ——上半年业绩靓丽，市场份额持续提升 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 08 月 27 日 | | --- | --- | | 收盘价（港币） | 54.55 | | 恒生中国企业指数 | 9020.26 | | 52 周最高/最低（港币） | 64.45/18.52 | | H 股市值（亿港币） | 657.07 | | 流通 H 股（百万股） | 1,204.52 | | 汇率（人民币/港币） | 1.0953 | 上 市 公 司 -5% 95% 195% 295% HSCEI 药明合联 资料来源：Bloomberg 相关研究 《 WuXi XDC Cayman Inc.(02268):Strong results with the rising number of new projects 》 2025/03/31 证券分析师 周文远 A0230518110003 zhouwy@swsresearch.com 研究支持 胡梦婷 A0230524060004 humt@swsresearch. ...

Investment Rating - The investment rating for Mixue Group has been upgraded from Outperform to Buy, indicating a strong expectation of performance exceeding the market by over 20% [6][11][23] Core Insights - Mixue Group reported a revenue of Rmb14.9 billion for 1H25, representing a year-on-year growth of 39%, and a net profit of Rmb2.7 billion, which is a 44% increase year-on-year. The net profit margin improved by 0.6 percentage points to 18.3%, exceeding expectations primarily due to higher-than-expected new store openings [6][7][11] - The forecast for net profit in 2025 has been raised from Rmb5.2 billion to Rmb5.6 billion, while the forecasts for 2026 and 2027 remain at Rmb6.2 billion and Rmb7.4 billion, respectively. The target price has been adjusted from HK$565 to HK$566, reflecting a 23% upside potential [6][7][11] Financial Data and Earnings Forecast - Revenue projections for Mixue Group are as follows: - 2023: Rmb20.302 billion - 2024: Rmb24.829 billion - 2025E: Rmb32.459 billion - 2026E: Rmb36.238 billion - 2027E: Rmb42.233 billion - Year-on-year growth rates for revenue are projected at 50% for 2023, 22% for 2024, 31% for 2025, 12% for 2026, and 17% for 2027 [5][14] - Net profit projections are as follows: - 2023: Rmb3.187 billion - 2024: Rmb4.454 billion - 2025E: Rmb5.569 billion - 2026E: Rmb6.183 billion - 2027E: Rmb7.369 billion - Year-on-year growth rates for net profit are projected at 57% for 2023, 41% for 2024, 25% for 2025, 11% for 2026, and 19% for 2027 [5][14] Store Expansion and Market Presence - The total number of global stores exceeded 53,000, with a net addition of 9,796 stores in 1H25, including 9,668 in mainland China and 128 overseas. The total store count increased by 23% year-on-year [6][8] - The company is expanding its overseas market presence, with positive growth in daily sales in Southeast Asia and plans for new store openings in the Eastern US, Western US, Mexico, and Brazil [9][11] Brand Development - The Lucky Coffee brand complements Mixue Bingcheng stores by focusing on freshly-made coffee, utilizing semi-automatic machines for on-site grinding, while Mixue Bingcheng primarily offers coffee as a supplement to its tea menu [10][11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company achieved revenue of 7.338 billion yuan in Q2 2025, representing a year-over-year increase of 19.8%, and adjusted net profit of 561 million yuan, marking a return to profitability [6] - The gross margin for Q2 was 36.5%, an increase of 6.5 percentage points year-over-year [6] - Mobile game revenue reached 1.61 billion yuan, up 60% year-over-year; value-added services revenue was 2.84 billion yuan, up 11% year-over-year; advertising revenue exceeded expectations at 2.45 billion yuan, up 20% year-over-year; while IP derivatives and other income decreased by 15% year-over-year to 440 million yuan [6][7] - The core user base is growing healthily, with daily active users (DAU) reaching 108 million, up 6% year-over-year, and monthly active users (MAU) at 365 million, up 8% year-over-year [8] - The company expects revenues of 30.08 billion yuan, 33.12 billion yuan, and 36.15 billion yuan for 2025, 2026, and 2027 respectively, with adjusted net profits of 2.11 billion yuan, 2.96 billion yuan, and 3.89 billion yuan for the same years [9] Financial Summary - Total revenue for 2024 is projected at 26.832 billion yuan, with a year-over-year growth of 19.1% [12] - Adjusted net profit for 2025 is expected to be 2.114 billion yuan, a significant increase from a loss of 22 million yuan in 2024 [12] - The company’s gross margin is projected to improve from 32.7% in 2024 to 39.7% in 2027 [14] - The earnings per share (EPS) is forecasted to rise from -0.05 yuan in 2024 to 9.42 yuan in 2027 [15]

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268 HK) with a target price of HKD 82.24 [7][12] Core Insights - The demand for ADC (Antibody-Drug Conjugates) continues to grow, with the company experiencing significant order increases and steady capacity expansion [1][2] - WuXi AppTec is reaffirmed as a leader in the global ADC/XDC CRDMO (Contract Research, Development, and Manufacturing Organization) sector, with strong upward momentum in performance [1][7] Financial Performance - For the first half of 2025, the company reported revenues of RMB 2.701 billion, a year-on-year increase of 62%, and adjusted net profit of RMB 733 million, up nearly 70% [2] - The overseas revenue contribution reached 82%, an increase of 8 percentage points compared to 2024 [2] - The company's market share in the global ADC CRDMO market rose from 9.9% in 2022 to 22.2% in the first half of 2025 [2] Industry Dynamics - The ADC/XDC sector shows strong long-term growth potential, with four ADC products approved for market from Q4 2024 to H1 2025, and many more expected in the next 3-5 years [2] - There are approximately 2,200 candidate conjugated drugs globally, with 21% being new ADCs, indicating a robust pipeline for future development [2] Client Expansion and Orders - In H1 2025, the company signed 37 new iCMC contracts, a historical high for the period, with expectations for the total number of new projects in 2025 to exceed the previous two years [3] - The backlog of orders reached USD 1.329 billion, a year-on-year increase of 57.9%, with North America leading in new contracts [3] - The company added 64 new clients in H1 2025, maintaining active collaborations with 13 of the top 20 multinational corporations, contributing approximately 33% of revenue [3] Capacity Expansion and Operational Efficiency - WuXi AppTec is set to launch new production facilities in Wuxi and Singapore, with a planned capital expenditure exceeding RMB 7 billion by 2029 [4] - The gross margin for H1 2025 was 36.1%, an increase of 4 percentage points year-on-year, with expectations for further improvement in 2025 [4] - The adjusted net profit margin for H1 2025 was 27.1%, reflecting a positive trend amid company growth [4] Profit Forecast and Valuation - The adjusted net profit forecast for 2025-2027 is RMB 1.72 billion, RMB 2.37 billion, and RMB 2.80 billion, respectively, with a CAGR of 34% [5] - The target price is based on a PEG ratio of 1.59x, consistent with comparable company expectations [5][12]

Investment Rating - The report upgrades the investment rating for Nongfu Spring (9633.HK) to "Buy" [1][9]. Core Views - The company achieved impressive performance in H1 2025, with revenue of 25.622 billion yuan, a year-on-year increase of 15.6%, and a net profit attributable to shareholders of 7.622 billion yuan, up 22.1% year-on-year [4][9]. - The strong recovery in bottled water sales and double-digit growth in ready-to-drink tea revenue were highlighted, driven by improved public sentiment and increased domestic tourism [5][7]. - The company is expected to maintain robust growth in 2025, with a projected revenue increase of double digits and improved profit margins due to cost advantages and product structure optimization [8][9]. Summary by Sections Financial Performance - In H1 2025, Nongfu Spring's gross margin reached 60.3%, up 1.5 percentage points year-on-year, attributed to lower raw material costs and improved revenue scale [6]. - The sales expense ratio decreased to 19.6%, down 2.8 percentage points year-on-year, due to reduced advertising and promotional expenses [6]. Product Categories - Bottled Water: Revenue of 9.443 billion yuan, up 10.7% year-on-year, supported by improved public sentiment and increased consumer awareness of natural water [5][7]. - Ready-to-Drink Tea: Revenue of 10.089 billion yuan, a 19.7% increase year-on-year, driven by the brand's strong market position and successful promotional activities [5][8]. - Functional Beverages: Revenue of 2.898 billion yuan, up 13.6% year-on-year, due to enhanced brand exposure [5]. - Juice Beverages: Revenue of 2.564 billion yuan, a 21.3% increase year-on-year, supported by new product launches and channel expansion [5]. - Other Products: Revenue of 629 million yuan, up 14.8% year-on-year, reflecting the company's adaptation to health trends [5]. Future Outlook - The company is expected to achieve a net profit of 14.838 billion yuan in 2025, with a growth rate of 22.4% [10]. - The report anticipates continued growth in the ready-to-drink tea segment and a recovery in bottled water sales, with a focus on new product development and market expansion [8][9].